BioElectronics Corporation's Temple University Diabetic Foot Ulcer Study Published in the International Wound Journal
Published: Sep 27, 2011
FREDERICK, MD--(Marketwire - September 27, 2011) -
"We are very pleased to be able to present this data to the medical field as we believe that our technology could contribute significantly in helping patients suffering from chronic wounds," commented Ian Rawe, PhD, principal author of the article. "The cost of health continues to increase and the treatment of diabetic ulcers runs into the billions of dollars annually. With our innovative products we are able to positively impact, not only the suffering, but also the health care costs involved in the treatment of chronic wounds."
Arnon Horev, VP Sales and Marketing of BioElectronics, commented, "This study on chronic wounds clearly demonstrates something we have known for a very long time. Our technology changes the game for wound healing. Not only are our devices effective in speeding healing and reducing levels of pain, it is also wearable, which makes it a viable solution to alleviate chronic body aches and pains. We plan to use the data from this study to further enhance our international marketing and future applications with the US FDA."
The article, titled, "The use of a portable, wearable form of pulsed radio frequency electromagnetic energy device for the healing of recalcitrant ulcers: a case report." can be viewed at: http://www.ncbi.nlm.nih.gov/pubmed/21933346.
About BioElectronics Corporation
BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ Menstrual Cycle Pain Therapy, and RecoveryRx™ for surgical procedures and wound care. The unique therapy delivery system, using patented technology, provides a cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.